fluphenazine depot has been researched along with Chronic Disease in 33 studies
fluphenazine decanoate : The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the feasibility and impact of gradually reducing relatively high doses of fluphenazine decanoate by one-half for chronically impaired, poor inner-city patients with schizophrenia." | 5.07 | A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. ( Egan, GJ; Gloersen, BA; Inderbitzin, LB; Lewine, RR; Scheller-Gilkey, G; Swofford, CD; Vidanagama, BP; Waternaux, C, 1994) |
| "This study uses the highly sensitive method of gas chromatography/mass spectrometry to compare the basic steady-state pharmacokinetic parameters of two fluphenazine decanoate formulations." | 2.67 | The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection. ( Brown, WA; Friedhoff, LT; Glazer, WM; Marder, SR, 1992) |
| " This means that it has a long half-life measurable in months rather than weeks." | 1.28 | Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. ( Cooper, TB; Levinson, DF; Lo, ES; Simpson, GM; Stephanos, MJ; Yadalam, KG, 1990) |
| "Haloperidol was given to 8 patients for 10 days (group A: 0." | 1.27 | Effects of neuroleptic treatments on peripheral opioid secretion. ( Bellodi, L; Brambilla, F; Brancato, V; Facchinetti, F; Genazzani, AR; Petraglia, F; Smeraldi, E, 1987) |
| "This high rate of relapse is viewed as indicating the need for continued medication in most chronic schizophrenic patients." | 1.26 | Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. ( Aderounmu, AF; Odejide, OA, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (66.67) | 18.7374 |
| 1990's | 10 (30.30) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baptista, T | 1 |
| Martinez, M | 1 |
| Lacruz, A | 1 |
| Arellano, A | 1 |
| Mendoza, S | 1 |
| Beaulieu, S | 1 |
| Hernández, L | 1 |
| Contreras, Q | 1 |
| Galeazzi, T | 1 |
| Vargas, D | 1 |
| Small, JG | 1 |
| Kellams, J | 1 |
| Walker, CA | 1 |
| Johnson, DA | 1 |
| Pasterski, G | 1 |
| Ludlow, JM | 1 |
| Street, K | 1 |
| Taylor, RD | 1 |
| Lapierre, YD | 1 |
| von Frenckell, R | 1 |
| Müller, P | 1 |
| Dencker, SJ | 1 |
| Wistedt, B | 2 |
| Ranta, J | 1 |
| Marriott, P | 1 |
| Pansa, M | 1 |
| Hiep, A | 1 |
| Odejide, OA | 1 |
| Aderounmu, AF | 1 |
| McCreadie, R | 1 |
| Mackie, M | 1 |
| Morrison, D | 1 |
| Kidd, J | 1 |
| Filotto, JF | 1 |
| Inderbitzin, LB | 1 |
| Lewine, RR | 1 |
| Scheller-Gilkey, G | 1 |
| Swofford, CD | 1 |
| Egan, GJ | 1 |
| Gloersen, BA | 1 |
| Vidanagama, BP | 1 |
| Waternaux, C | 1 |
| Stone, AM | 1 |
| Greenstein, RA | 1 |
| Gamble, G | 2 |
| McLellan, AT | 1 |
| Dhopesh, V | 1 |
| Macfadden, A | 1 |
| Maany, I | 1 |
| Heresco-Levy, U | 1 |
| Greenberg, D | 1 |
| Lerer, B | 1 |
| Javitt, DC | 1 |
| Brown, WA | 3 |
| Moore, DB | 1 |
| Kelly, DL | 1 |
| Sherr, JD | 1 |
| Love, RC | 1 |
| Conley, RR | 1 |
| Soni, SD | 3 |
| Sampath, G | 1 |
| Shah, A | 1 |
| Krska, J | 1 |
| Glazer, WM | 1 |
| Friedhoff, LT | 1 |
| Marder, SR | 1 |
| Samuel, G | 1 |
| Brownlee, M | 1 |
| Simpson, GM | 1 |
| Yadalam, KG | 1 |
| Levinson, DF | 1 |
| Stephanos, MJ | 1 |
| Lo, ES | 1 |
| Cooper, TB | 1 |
| Lazarus, A | 1 |
| Kolakowska, T | 1 |
| Williams, AO | 1 |
| Ardern, M | 1 |
| Reveley, MA | 1 |
| Brambilla, F | 1 |
| Facchinetti, F | 1 |
| Petraglia, F | 1 |
| Smeraldi, E | 1 |
| Bellodi, L | 1 |
| Brancato, V | 1 |
| Genazzani, AR | 1 |
| Wiles, D | 1 |
| Schiff, AA | 1 |
| Bamrah, JS | 1 |
| McKane, JP | 1 |
| Robinson, AD | 1 |
| Wiles, DH | 1 |
| McCreadie, RG | 1 |
| Stirling, GS | 1 |
| Hirschberg, E | 1 |
| Jayaram, G | 1 |
| Coyle, J | 1 |
| Tune, L | 1 |
| Kong, DS | 1 |
| Yeo, SH | 1 |
| Curson, DA | 1 |
| Barnes, TR | 1 |
| Bamber, RW | 1 |
| Platt, SD | 1 |
| Hirsch, SR | 1 |
| Duffy, JC | 1 |
| Silver, MA | 1 |
10 trials available for fluphenazine depot and Chronic Disease
| Article | Year |
|---|---|
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Blood Glucose; Chronic Disease; Delayed-Acti | 2007 |
A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Topics: Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Clopenthixol; Delayed-Action Prepar | 1983 |
Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Depression; Double-Blind Method; Flupenthixo | 1983 |
A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Topics: Adult; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action Preparations; Double | 1994 |
Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluph | 1997 |
The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flup | 1992 |
Psychiatrists and citizens.
Topics: Chronic Disease; Double-Blind Method; Ethics, Medical; Fluphenazine; Humans; Informed Consent; Schiz | 1991 |
Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; H | 1987 |
A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; | 1986 |
Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; | 1985 |
23 other studies available for fluphenazine depot and Chronic Disease
| Article | Year |
|---|---|
Early hospital experience with fluphenazine decanoate.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Fluphenazine; Fo | 1974 |
The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Flupenthixol; Fl | 1983 |
AMDP psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Female; Fluphenazine; Humans; Male; Middle | 1983 |
[What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
Topics: Ambulatory Care; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Administration Sch | 1983 |
The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
Topics: Administration, Oral; Antipsychotic Agents; Basal Ganglia Diseases; Biological Availability; Chronic | 1984 |
Intervals between long acting neuroleptics: outcome and re-admission variables.
Topics: Age Factors; Chronic Disease; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Patient Readmis | 1984 |
Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Topics: Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Fluphenazine; Humans; Psychiatric | 1982 |
Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
Topics: Adult; Aged; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induced; Fluphenazine; Humans; M | 1982 |
[Group psychotherapy of chronic schizophrenics in an external milieu].
Topics: Adult; Ambulatory Care; Chronic Disease; Female; Fluphenazine; Humans; Male; Middle Aged; Psychoanal | 1981 |
Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
Topics: Adult; Ambulatory Care; Chronic Disease; Cocaine; Combined Modality Therapy; Comorbidity; Delayed-Ac | 1993 |
Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cocaine; Comorbidity; Delayed-Action Preparations; Flu | 1997 |
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival | 1998 |
Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
Topics: Administration, Oral; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Dyskinesia, | 1992 |
Alcohol abuse in chronic schizophrenics: implications for management in the community.
Topics: Adult; Alcohol Drinking; Alcoholism; Chronic Disease; Community Mental Health Services; Delayed-Acti | 1991 |
Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Fluphenazine; Haloperidol; Humans; Injections, In | 1990 |
Heatstroke in a chronic schizophrenic patient treated with high-potency neuroleptics.
Topics: Antipsychotic Agents; Benztropine; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, | 1985 |
Tardive dyskinesia in schizophrenics under 60 years of age.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Dyskinesia, Drug-Ind | 1986 |
Effects of neuroleptic treatments on peripheral opioid secretion.
Topics: Adult; Antipsychotic Agents; beta-Endorphin; beta-Lipotropin; Chlorpromazine; Chronic Disease; Diben | 1987 |
Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
Topics: Adolescent; Adult; Chronic Disease; Delayed-Action Preparations; Fluphenazine; Humans; Injections, I | 1988 |
Long persisting drug-induced parkinsonism--a case report.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Female; Fluphenazine; Humans; Parkinson Disease | 1987 |
Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chronic Disease; Female; Fluphenazine; Humans; Injections, | 1986 |
Flupenthixol decanoate and fluphenazine decanoate in chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; Flupenthixol; Fluphenazine; Humans; Male; Middle Aged; Schizophrenia | 1985 |
Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Topics: Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Female; Fluphenazine; Humans; Male; | 1985 |